Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells

Journal of Immunotherapy

Volumn 40, Issue 3, 2017, Pages 104-107

  Tanyi, Janos L ^a   Stashwick, Caitlin ^b   Plesa, Gabriela ^a   Morgan, Mark A ^a   Porter, David ^a   Maus, Marcela V ^c   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Penn Medicine Lancaster General Health Physicians Geriatrics   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

compartment cytokine release syndrome; mesothelin redirected CAR T Cell; ovarian cancer

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; C REACTIVE PROTEIN; CARBOPLATIN; CHIMERIC ANTIGEN RECEPTOR; DOXORUBICIN; FERRITIN; GEMCITABINE; HYPERTENSIVE FACTOR; INTERLEUKIN 6; MESOTHELIN; PACLITAXEL; PEMETREXED; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THALIDOMIDE; TOCILIZUMAB; TOPOTECAN; ANTIGEN T CELL RECEPTOR, ZETA CHAIN; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYBRID PROTEIN; INTERLEUKIN 6 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; TNFRSF9 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9;

ADULT; ARTICLE; BLOOD; CANCER RECURRENCE; CASE REPORT; CELL ACTIVATION; CELL SELECTION; CELL THERAPY; CYTOKINE RELEASE SYNDROME; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GENE MUTATION; HUMAN; HUMAN CELL; HYPOTENSION; MIDDLE AGED; OVARY CANCER; PLEURA CAVITY; PLEURA FLUID; PRIORITY JOURNAL; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; COMPLICATION; FATALITY; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; OVARY TUMOR; PHYSIOLOGY; PROCEDURES; SYNDROME; TRANSPLANTATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; CELLS, CULTURED; FATAL OUTCOME; FEMALE; FEVER; GPI-LINKED PROTEINS; HUMANS; HYPOTENSION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-6; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; SYNDROME; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 9;

EID: 85013798313     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000160     Document Type: Article

References (9)

1. Davila ML, Sauter C, Brentjens R. CD19-targeted T cells for hematologic malignancies: clinical experience to date. Cancer J. 2015;21:470-474.
2. Frey NV, Porter DL. CAR T-cells merge into the fast lane of cancer care. Am J Hematol. 2016;91:146-150.
3. Van den Berg JH, Gomez-Eerland R, Van de Wiel B, et al. Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol Ther. 2015;23:1541-1550.
4. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-851.
5. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.
6. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6: 224ra25.
7. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/ CD28 costimulation. Blood. 2006;107:1325-1331.
8. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.
9. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. PNAS. 2009; 106:3360-3365.